VRC 307: A D/B Randomized Ph. I Study of Safety/Immunogenicity of a Prime-Boost Schedule of an Investigational DNA Influenza Vaccine, Followed by the Seasonal Influenza Trivalent Inactivated Vaccine (TIV), Compared to TIV Alone in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus DNA vaccine
- Indications Influenza virus infections
- Focus Adverse reactions